| abstract |
The present disclosure describes a pharmaceutical composition comprising at least one antibody targeting one or more of cytokines selected from Macrophage colony-stimulating factor (M-CSF), lnterleukin-1 beta (IL-1 β), CCL-1 (I- 309) and Eotaxin-2 (CCL24) and at least one mesenchymal stromal cell-derived protein selected from Prostaglandin E2 (PGE2), Osteoprotegerin (OPG), CCL7 (MCP-3), CCL8 (MCP-2), CCL20 (MIP-3α), CXCL5 (ENA-78), Interleukin 10 (IL-10) and CXCL6 (GCP-2). In a preferred embodiment, a composition comprising anti-CCL24 antibody and CXCL5 is disclosed. The present disclosure also describes the use of said pharmaceutical composition for treating immunological diseases, for example alloimmune or autoimmune diseases and further discloses the use of the pharmaceutical composition for immunomodulation. |